Do you get tired of offering patients with autoimmune diseases treatment options that aren’t true solutions? We don’t blame you—there simply aren’t great options out there. Some treatments ease symptoms but are paired with serious side effects. Others have less serious side effects but are also less effective. As a result of these limited options patients are living with daily disruptions, serious adverse side effects, and often still require major surgeries. We are confident there is a better way.
We are developing new treatments for autoimmune diseases that will transform therapeutic paradigms and clinical practice. No longer will it be required for patients to choose between safety and efficacy. We also are striving to present physicians and patients with treatment options that do not disrupt everyday living—no more injections or infusions. We aim to develop surgery-sparing treatments.
At present, we have developed a first-in-class, oral therapy for Inflammatory Bowel Disease (IBD) and its two clinical manifestations: Crohn’s disease and ulcerative colitis, that is showing remarkable preclinical results. Our leading asset for IBD is entering clinical trials in 2018 which means our team is poised to soon address the unmet clinical need in IBD and offer IBD patients a better way.
Our team has no plans of stopping with IBD. We know IBD is one of over 100 autoimmune diseases. We will continue to work tirelessly to develop lasting solutions to autoimmune diseases that physicians feel good about offering patients. We want better patient outcomes—for the present and for their future.